title: The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).
abstract: BACKGROUND
  Hypertrophic pulmonary osteoarthropathy (HPOA) secondary to bronchogenic carcinoma can be associated with severe, disabling pain which is not always responsive to conventional treatment.
  
  
  OBJECTIVE
  To report on the use of pamidronate to control resistant pain in HPOA in three cases.
  
  
  METHODS
  A retrospective review of reported pain, chest X-ray and radionuclide bone scans was made.
  
  
  RESULTS
  Pain relief was achieved in all three cases together with reduced radiolabel uptake in two cases.
  
  
  CONCLUSIONS
  Pamidronate appears to be an effective therapy for HPOA. Further investigation is warranted.
authors.affiliation: Department of Oncology, Royal Hobart Hospital, Tasmania.
authors.forename: D
authors.initials: D
authors.lastname: Speden
authors.forename: F
authors.initials: F
authors.lastname: Nicklason
authors.forename: H
authors.initials: H
authors.lastname: Francis
authors.forename: J
authors.initials: J
authors.lastname: Ward
mesh_terms: D000230:Adenocarcinoma / Q000150:complications*; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications*; D010005:Osteoarthropathy, Secondary Hypertrophic / Q000188:drug therapy* / Q000209:etiology; D010166:Palliative Care; D000077268:Pamidronate
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate